Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Geltor Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct examiners and distinct art units, showing a diverse distribution of the portfolio's current legal challenges across different regulatory groups. This variety indicates that the company is navigating multiple technical standards and examiner preferences simultaneously within the same technology area.
KOMATSU, LI N is identified as the busiest examiner, currently handling 1 pending office action. Since the total count of pending actions is split between the identified busiest examiner and another individual, the workload is distributed. This distribution across multiple art units may require varied strategies depending on the specific examiner's tendencies and the technical requirements of each unit. Managing the pending actions across multiple examiners requires a broader tactical approach than a more concentrated portfolio would demand. The company must address the 1 action under KOMATSU, LI N while also managing the remaining case.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOMATSU, LI N | 1 | 59.8% | +71.1% |
| SABILA, MERCY HELLEN | 1 | 57.0% | +46.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18750919 | RECOMBINANT COLLAGEN AND ELASTIN MOLECULES AND USES THEREOF | KOMATSU, LI N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18191556 | COMPOSITIONS COMPRISING COMBINATIONS OF COLLAGEN OR ELASTIN POLYPEPTIDES WITH ACTIVE INGREDIENTS AND METHODS OF USING SAME | SABILA, MERCY HELLEN | 12d |
| 18750919 | RECOMBINANT COLLAGEN AND ELASTIN MOLECULES AND USES THEREOF | KOMATSU, LI N | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18750919 | RECOMBINANT COLLAGEN AND ELASTIN MOLECULES AND USES THEREOF | KOMATSU, LI N | 1658 | §101§102§112DP | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18191556 | COMPOSITIONS COMPRISING COMBINATIONS OF COLLAGEN OR ELASTIN POLYPEPTIDES WITH ACTIVE INGREDIENTS AND METHODS OF USING SAME | SABILA, MERCY HELLEN | 1654 | §103§112DP | Final Rejection | 12d | Pending | Mar 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial